We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV
Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
OBJECTIVE Erlotinib has been reported to be useful for treatment of non-small-cell lung cancer harboring mutation of the epidermal growth factor receptor gene EGFR-mt . However , no prospect i ve trial has yet assessed the utility of erlotinib in Japanese patients . METHODS Patients with EGFR-mt ( exon 19/21 ) non-small-cell lung cancer who had previously received one to two chemotherapy regimens were enrolled in this trial . Erlotinib was initially administered at a dose of 150 mg/day orally until disease progression or unacceptable toxicities occurred . The primary endpoint was the objective response rate . RESULTS Twenty-six patients were enrolled between February 2009 and January 2011 .  Objective response was observed in 14 patients ( 53.8 % , 95 % confidence interval : 33.4 - 73.4 % ) , and the disease control rate reached 80.8 % ( 95 % confidence interval : 60.7 - 93.5 % ) . After a median follow-up time of 17.3 months ( range : 5.8 - 29.5 months ) , the median progression-free survival was 9.3 months ( 95 % confidence interval : 7.6 - 11.6 months ) . The median survival time is yet to be determined . Major toxicities were skin disorder and liver dysfunction ; most episodes were grade 2 or less , and all were tolerable . Only one patient with grade 3 skin rash discontinued the study . No patients developed interstitial lung disease , and there were no treatment-related deaths . CONCLUSIONS This prospect i ve study is the first to have investigated the usefulness of erlotinib in Japanese patients with previously treated EGFR-mt non-small-cell lung cancer . Although this trial could not meet the primary endpoint , erlotinib was well tolerated and showed clinical benefit such as promising disease control rate or progression-free survival in this population , similar to gefitinib
We believe that this attempt enables clinicians to choose appropriate treatment easier .
According to rapid development of chemotherapy in advanced non-small cell lung cancer ( NSCLC ) , the Japan Lung Cancer Society has been up date d its own guideline annually since 2010 .
Recently , we have had various types of chemotherapeutic drugs like kinase inhibitors or immune-checkpoint inhibitors .
Thus , the guideline proposes to categorize patients into three entities : ( 1 ) driver oncogene-positive , ( 2 ) PD-L1 ≥ 50 % , and ( 3 ) others .
Here , we report an English version of the Japan Lung Cancer Society Guidelines 2018 for NSCLC , stages IV